This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Astellas Pharma Gmbh. Active years: 2011-2012.
Company Filing History:
Years Active: 2011-2012
Title: Hidetaka Kaku: Innovator in Pharmaceutical Chemistry
Introduction
Hidetaka Kaku is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds for the treatment of irritable bowel syndrome (IBS). With a total of 2 patents, Kaku's work focuses on innovative solutions to complex medical problems.
Latest Patents
Kaku's latest patents include a pyrrole derivative or salt thereof, which aims to provide a compound useful for the prevention and/or treatment of diseases related to the 5-HT receptor. This compound exhibits strong antagonism for both the 5-HT receptor and the 5-HT receptor, demonstrating effective pharmacological action compared to selective antagonists. Another notable patent is an amide derivative or salt thereof, which also shows strong antagonism for the same receptors, further supporting its potential in treating IBS.
Career Highlights
Hidetaka Kaku is currently associated with Astellas Pharma GmbH, where he continues to innovate in the pharmaceutical sector. His research has led to advancements that could significantly improve the quality of life for individuals suffering from IBS.
Collaborations
Kaku collaborates with esteemed colleagues such as Ryushi Seo and Hiroyoshi Yamada, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Hidetaka Kaku's contributions to pharmaceutical chemistry, particularly in the development of treatments for IBS, highlight his role as a key inventor in the field. His innovative patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.